PALATIN TECHNOLOGIES Forum: Community User: CologneFC

@ bussard1: Du glaubst doch nicht, dass hier das Ende der Fahenstange erreicht ist. Fantasie kommt doch erst noch in den Kurs :-)

Schade. Hätte gerne nochmal zugekauft.

Okok;))

naja, noch nen bisl früh, dass zu sagen. :-)

Du irrst dich;)

Mal schauen, ob die Amis Deine Meinung teilen?

Tippe zum WE auf Gewinnmitnahmen und hoffe dass die 80 Eurocent halten. Schöner wärs, ich irre mich :-)

Dafür bin ich auch!

Heute dürfte das Papier mal dauerhaft den Dollar überschreiten und nächste Woche gerne den Euro!

Ich glaube dass wir uns morgen bei 88 Cent einpendeln als kleine Korrektur

Was für ein run

denke 1$ könnte erstmal einen Widerstand markieren- wäre dann 88 Cent

Mein Gefühl sagt mir es geht weiter hoch ☝️

So I think that Vyleesi falls into a category where you're characterizing the blood pressure effect. The clinical risk is low and probably I don't think that they would necessarily have to go out and seek advice from an adcom. I think that the personnel that we've been working with the agency that are coming from the cardio legal group or are quite conversant with the type of study signs we're using and the potential risk of intermittent changes, small change in blood pressure. So I think that we're okay there. However, with that being said, we will be submitting the data back. The agency has the right to take -- to have additional time to review that data should they choose to do so. I don't think at the moment based on our discussions with them, that they will do that, but we always have to plan for that, that they could. Wieder Steve Willis, PTN

Steve Wills As Carl mentioned, the AI that we needed was, we needed more specificity, granularity around the specific protocol for approval in Europe. We have that now and as Carl mentioned, we were pleased with the response and the dialogue from IMA/CHMP. So that activity has definitely increased, not just us calling, but also inbound calls. We're actively and aggressively in discussions with all the regions outside of the already licensed territories of North America with AMAG, China with Fosun and South Korea with Kwangdong Pharmaceuticals. So we and as we get closer to the PDUFA date and the approval I'm very comfortable that these discussions will even advanced greater. We're also working closely with our existing rest of the world partners i.e. Fosun, Pharma and Kwangdong. They are in active discussions with the related regulatory FDI in China and the same equivalent in South Korea on planning their specific regulatory path. So we're very excited and enthusiastic with the activity and the interest and with the assumption and caveat that were approved in June. We would anticipate that frankly all the regions outside the existing territories would be licensed before the end of calendar 2019.

Was meint Ihr, korrigieren wir nochmal unter 80 Cent? Bin gespannt was die Amis heute draus machen :-)